Roswitha Kammler

TL;DR: The results of this study do not support using the presence or absence of hot flushes or the pharmacogenetic testing of CYP2D6 to determine whether to treat postmenopausal breast cancer patients with tamoxifen and support the hypothesis that reduced enzyme activity was associated with worse disease control.

TL;DR: This single-arm, multicentre, phase 1b-2 trial assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastzumab-resistant, advanced HER2-positive breast cancer.

TL;DR: The findings of the IBCSG 23-01 trial corroborate those obtained at 5 years and are consistent with those of the 10-year follow-up analysis of the Z0011 trial, and support the current practice of not doing an axillary dissection when the tumour burden in the sentinel nodes is minimal or moderate.

TL;DR: The BELIEF trial provides further evidence of benefit for the combined use of erlotinib and bevacizumab in patients with NSCLC harbouring activating EGFR mutations.

TL;DR: Afatinib did not show the expected potential for disease control in NSCLC, but more than half of the patients in the full cohort achieved disease control at 12 weeks.